Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

被引：131

作者：

Konteatis, Zenon ^{[1
]}

Artin, Erin ^{[1
,7
]}

Nicolay, Brandon ^{[1
]}

Straley, Kimberly ^{[1
,8
]}

Padyana, Anil K. ^{[1
]}

Jin, Lei ^{[1
]}

Chen, Yue ^{[1
]}

Narayaraswamy, Rohini ^{[1
]}

Tong, Shuilong ^{[2
]}

Wang, Feng ^{[3
]}

Zhou, Ding ^{[4
,9
]}

Cui, Dawei ^{[4
,10
]}

Cai, Zhenwei ^{[4
]}

Luo, Zhiyong ^{[5
]}

Fang, Cheng ^{[5
]}

Tang, Huachun ^{[5
]}

Lv, Xiaobing ^{[5
,14
]}

Nagaraja, Raj ^{[1
]}

Yang, Hua ^{[1
]}

Su, Shin-San M. ^{[1
,12
]}

Sui, Zhihua ^{[1
]}

Dang, Lenny ^{[1
]}

Yen, Katharine ^{[1
,13
]}

Popovici-Muller, Janeta ^{[1
,12
]}

Codega, Paolo ^{[6
,11
]}

Campos, Carl ^{[6
]}

Mellinghoff, Ingo K. ^{[6
]}

Biller, Scott A. ^{[1
]}

机构：

[1] Agios Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Viva Biotech, Shanghai 201203, Peoples R China

[3] Wuxi Biortus Biosci Co Ltd, Jiangyin 214437, Peoples R China

[4] PharmaResources, Shanghai 201201, Peoples R China

[5] ChemPartner, Shanghai 201203, Peoples R China

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[7] KSQ Therapeut, Cambridge, MA 02139 USA

[8] Vertex Pharmaceut, Boston, MA 02210 USA

[9] Zion Pharma, Shanghai 200000, Peoples R China

[10] Suzhou Zelgen Biopharmaceut, Kunshan 215300, Peoples R China

[11] Sundia, Shanghai 201203, Peoples R China

[12] Decibel Therapeut, Cambridge, MA 02215 USA

[13] Auron Therapeut, Wellesley, MA 02481 USA

[14] Italfarmaco SpA, I-20092 Cinisello Balsamo, Italy

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 02期

关键词：

Isocitrate dehydrogenase; mutant IDH1/mIDH2; AG-881; vorasidenib; 2-hydroxyglutarate; GENOMIC ANALYSIS; MUTATIONS;

D O I：

10.1021/acsmedchemlett.9b00509

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model. Vorasidenib represents a novel dual mIDH1/2 inhibitor and is currently in clinical development for the treatment of low-grade mIDH glioma.

引用

页码：101 / 107

页数：13

共 50 条

[21] Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
DiNardo, Courtney D.
de Botton, Stephane
Stein, Eytan M.
Roboz, Gail J.
Swords, Ronan T.
Pollyea, Daniel A.
Fathi, Amir T.
Collins, Robert
Altman, Jessica K.
Flinn, Ian W.
Mannis, Gabriel N.
Mims, Alice S.
Foran, James M.
Pigneux, Arnaud
Prince, Gabrielle T.
Uy, Geoffrey L.
Tallman, Martin S.
Kantarjian, Hagop M.
Liu, Hua
Attar, Eyal C.
Sacolick, Jennifer
Yen, Katharine
Hurov, Jonathan B.
Choe, Sung
Wu, Bin
Stone, Richard M.
BLOOD, 2016, 128 (22)
[22] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
de Botton, S.
Pollyea, D. A.
Stein, E. M.
DiNardo, C.
Fathi, A. T.
Roboz, G. J.
Collins, R.
Swords, R. T.
Flinn, I.
Altman, J. K.
Tallman, M. S.
Kantarjian, H.
Colby, K.
Fan, B.
Goldwasser, M.
Prahl, M.
Agresta, S.
Stone, R. M.
HAEMATOLOGICA, 2015, 100 : 214 - 215
[23] THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Nicolay, Brandon
Narayanaswamy, Rohini
Aguado, Elia
Nagaraja, Raj
Murtie, Josh
Liu, Guowen
Ishii, Yuko
NEURO-ONCOLOGY, 2017, 19 : 86 - 86
[24] Discovery of AG-221: A first-in-class inhibitor of IDH2 mutant enzymes for the treatment of acute myelogenous leukemia
Travins, Jeremy
Saunders, Jeffrey
Salituro, Francesco
Popovici-Muller, Janeta
Yen, Katharine
Straley, Kimberly
Hansen, Erica
Wang, Fang
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Silverman, Lee
Agresta, Sam
Su, Michael
Biller, Scott
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[25] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
Natsume, Atsushi
Wakabayashi, Toshihiko
Miyakita, Yasuji
Narita, Yoshitaka
Mineharu, Yohei
Arakawa, Yoshiki
Yamasaki, Fumiyuki
Sugiyama, Kazuhiko
Hata, Nobuhiro
Muragaki, Yoshihiro
Nishikawa, Ryo
Shinojima, Naoki
Kumabe, Toshihiro
Saito, Ryuta
Ito, Kazumi
Tachibana, Masaya
Kakurai, Yasuyuki
Nishijima, Soichiro
Tsubouchi, Hiroshi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
Ishii, Yuko
Sigel, Carlie
Lowery, Maeve A.
Goyal, Lipika
Gliser, Camelia
Jiang, Liewen
Pandya, Susan
Bin Wu
Choe, Sung
Deshpande, Vikram
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[27] INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
Mellinghoff, Ingo K.
Van den Bent, Martin J.
Clarke, Jennifer Leigh
Maher, Elizabeth Anne
Peters, Katherine B.
Touat, Mehdi
De Groot, John Frederick
De La Fuente, Macarena Ines
Arrillaga-Romany, Isabel
Wick, Wolfgang
Ellingson, Benjamin M.
Schoenfeld, Steven
Tai, Feng
Le, Kha
Lu, Min
Steelman, Lori
Hassan, Islam
Pandya, Shuchi Sumant
Wen, Patrick Y.
Cloughesy, Timothy Francis
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient's selection
Gatto, Lidia
Di Nunno, Vincenzo
Tosoni, Alicia
Bartolini, Stefania
Ranieri, Lucia
Franceschi, Enrico
FRONTIERS IN ONCOLOGY, 2024, 13
[29] Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation
Wen, Fei
Gui, Gang
Wang, Xiaoyu
Qin, Anqi
Ma, Tianfang
Chen, Hui
Li, Chunzheng
Zha, Xiaoming
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 8667 - 8692
[30] Vorasidenib- A Paradigm Shift in IDH1-or IDH2-Mutant Low-Grade Glioma Treatment
Malik, Hurais
Hudaib, Muhammad
Rehman, Abdul
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2024, 74 (10) : 1912 - 1913

← 1 2 3 4 5 →